–
9
7
7
,
9
7
6
t
fo
r
P
O
N
V
,
4
7
8
t
D
r
o
s
p
i
r
e
n
o
n
e
,
9
3
7
t
,
1
0
1
1
,
1
0
1
2
,
1
0
2
5
,
1
0
2
7
D
R
V
(
s
e
e
D
a
r
u
n
av
i
r
(
D
R
V)
)
D
T
a
P
(
s
e
e
D
i
p
h
t
h
e
ri
a
,
t
e
t
a
n
u
s
,
a
n
d
a
c
e
l
l
u
l
a
r
p
e
rt
u
s
s
i
s
(
D
T
a
P
)
)
D
T
I
C
(
s
e
e
D
a
c
a
rb
azi
n
e
(
D
T
I
C
)
)
D
u
l
a
g
l
u
t
i
d
e
,
1
1
2
6
–
1
1
2
7
,
1
1
3
9
D
u
l
e
r
a
(
s
e
e
M
o
m
e
t
a
s
o
n
e
/
fo
r
m
o
t
e
r
o
l
)
D
u
l
o
x
e
t
i
n
e
,
1
1
8
1
t
,
1
1
8
8
,
1
1
9
4
t
,
1
7
3
8
t
,
1
7
5
4
,
2
2
5
2
fo
r
d
e
p
r
e
s
s
iv
e
dis
o
r
d
e
r
s
,
1
8
1
9
t
,
1
8
2
0
t
,
1
8
2
1
t
fo
r
dia
b
e
t
e
s
,
1
1
4
5
,
2
2
2
6
t
fo
r
O
A
,
8
7
2
–
8
7
3
fo
r
s
e
r
o
t
o
nin
,
1
8
2
6
fo
r
s
tr
e
s
s
in
c
o
nt
in
e
n
c
e
,
2
2
5
2
D
u
ri
c
e
f
(
s
e
e
C
e
fa
d
r
o
x
i
l
)
D
u
t
a
s
t
e
ri
d
e
,
2
2
5
7
–
2
2
5
8
fo
r
B
P
H
,
2
2
5
7
–
2
2
5
8
fo
r
p
r
o
s
t
a
t
e
c
a
n
c
e
r
,
2
0
9
9
D
y
c
l
o
n
i
n
e
h
y
d
r
o
c
h
l
o
ri
d
e
,
1
9
7
4
D
y
m
i
s
t
a
(
s
e
e
az
e
l
a
s
t
i
n
e
H
C
l/
fl
u
t
i
c
a
s
o
n
e
p
r
o
p
i
o
n
a
t
e
)
D
y
n
a
b
a
c
(
s
e
e
D
i
ri
t
h
r
o
m
y
c
i
n
)
EE
c
a
m
s
u
l
e
,
8
4
9
t
,
8
5
2
E
c
h
i
n
a
c
e
a
,
1
6
6
1
E
c
h
i
n
o
c
a
n
d
i
n
s
,
1
5
6
9
,
1
6
2
5
,
1
6
2
9
t
,
1
6
3
1
,
1
6
3
2
,
1
6
3
6
,
1
6
4
0
,
1
6
4
3
E
c
h
o
t
h
i
o
p
h
a
t
e
i
o
d
i
d
e
,
1
1
5
2
–
1
1
5
3
E
c
o
n
az
o
l
e
,
1
6
2
4
t
E
c
s
t
a
s
y
(
s
e
e
3
,
4
-
m
e
t
h
yl
e
n
e
d
i
o
x
y
m
e
t
h
a
m
p
h
e
t
a
m
i
n
e
)
E
d
l
u
a
r
,
fo
r
t
r
e
a
t
m
e
n
t
o
f
i
n
s
o
m
n
i
a
,
1
7
6
7
t
E
d
o
x
a
b
a
n
,
1
3
0
7
t
fo
r
p
r
e
v
e
nt
io
n
o
f
s
tr
o
ke
,
1
7
8
,
3
1
7
–
3
1
8
E
fav
i
r
e
n
z
(
E
F
V)
,
9
4
2
t
fo
r
H
I
V
,
1
5
8
0
t
fo
r
H
I
V
in
la
b
o
r
,
9
9
6
E
ffe
x
o
r
(
s
e
e
Ve
n
l
a
fa
x
i
n
e
)
Effexor XR (see Venlafaxine)
EFV (see Efavirenz (EFV))
EGFR inhibitors (see Epidermal growth factor receptor (EGFR) inhibitors)
Eicosopentanoic acid (EPA), 125–126
Elbasvir, for HAV, 1688, 1689
Eldepryl (see Selegiline)
Elestat (see Epinastine)
Elestrin (see Estradiol gel; Estradiol topical emulsion/gel/solution)
Eletriptan, 1238t, 1239
Ellence (see Epirubicin)
Elotuzumab, 469t
Eloxatin (see Oxaliplatin)
Elspar (see Asparaginase)
Eluxadoline (Viberzi), 536
Emadine (see Emedastine)
Emedastine (Emadine), 439t
Emend (see Aprepitant; Fosaprepitant)
Emollients, for psoriasis, 835t
Empagliflozin, 1129–1130
Empiric antibiotics, 661
Empiric antifungal therapy, 1641
Emtricitabine (FTC), 1679
for HIV, 1577t
Enalaprilat (Vasotec IV), 171, 281–282, 281t, 335t, 2223
for hypertension, 153t, 344
Encainide, and PVC, 323
Enfuvirtide (T-20) Fuzeon, for HIV, 1580t
Engerix-B, 1355
Enjuvia (see Synthetic conjugated estrogens)
Enoxaparin, 177t, 188t, 189, 251, 252, 677–678
for ACS, 240t
LMWH, 656
and UFH, 254
Ensulizole, 849t
Entacapone, 1250t, 1251t, 1263–1264
adverse effects of, 1264
dose of, 1264
pharmacologic and pharmacokinetic properties of, 1263t
Entecavir, 1680
for HBV, 1678
Entocort EC, 523
Entresto (see Sacubitril/valsartan)
Enzalutamide, for prostate cancer, 2095
EPA (see Eicosopentanoic acid (EPA))
Epanova, 126
Ephedrine, in treatment of IDH, 657
Epidermal growth factor receptor (EGFR) inhibitors, 1978
Epinastine (Elestat), 439t
Epinephrine, 445, 446t, 2207t, 2208
for anaphylaxis, 687–688, 689t
for cardiogenic shock, 363t, 364
for cardiopulmonary arrest, 330–331
dose of, 330
for septic shock, 371
EpiPen 2-Pak, 446t
EpiPen Jr 2-Pak, 446t
Epipodophyllotoxins, 1981t
Epirubicin (Ellence), 469t, 1978–1979t, 1988
and hepatic dysfunction, 1996t
Eplerenone, 543
for hypertension, 140, 157
side effects of, 257
Epoetin alfa, 615
for anemia, 1942
Epoprostenol, 924
Epoxy resin, 822t
Eprosartan mesylate, for hypertension, 154t
EPT therapy (see Estrogen/progestogen (EPT) therapy)
Eptifibatide, for ACS, 237
Erbitux (see Cetuximab)
Ergocalciferol, 621
Ergot alkaloids
adverse effects of, 1239–1240
for migraine headache, 1239
Ergotamine, and lactation, 1003t
Eribulin, 469t
Erlotinib (Tarceva), 470t, 2064–2066
drug interaction with smoking, 1906t
Ertapenem (Invanz), 1326t
dosing of, 1337t
for gram-negative aerobes, 1327t
for UTI, 1497t
Erythrocin (see Erythromycin)
Erythromycin, 120t, 128, 828, 830, 942t, 1325t, 1371, 2163, 2163t
for acne, 828, 830
adverse effects of, 1332t
for aerobic gram-positive cocci, 1326t
and breast milk, 1001
for BV, 995
for Campylobacter infection, 1459
and dyspepsia, 487
for GBS infection, 995
for RMSF, 1725
for skin and soft tissue infections, 1547
for TBRF, 1722
Erythropoietic therapy, for anemia, 1942
Escitalopram (Lexapro), 1027t, 1036t, 1738, 1738t, 1748
for depressive disorders, 1819t, 1820t, 1821t
for diabetes, 2226t
for panic disorder, 1748
for PTSD, 1754
for SAD, 1752
for vasomotor symptoms, 1036t
ESHAP, for aggressive lymphomas, 2041–2042
Eslicarbazepine, 1279t, 1281
for seizures, 1286t
Esmolol (Brevibloc), 335t
for hypertension, 346
Esomeprazole, 228, 483t, 484, 485, 502, 1216t, 2163t
for end-of-life care, 95
for preventing SRMB, 515t
Estazolam, 1737t, 1767t
Esterified estrogen (Menest), 1033t
Estrace (see Estradiol cream)
Estradiol acetate tablet (Femtrace), 1033t
Estradiol acetate vaginal ring (Femring), 1033t
Estradiol cream (Estrace), 1033t, 2218
Estradiol gel (Divigel; Elestrin; Estrogel), 1033t
Estradiol hemihydrate tablets (Vagifem and Vagifem LD), 1033t
Estradiol hemihydrate tablets (Vagifem), 1033t
Estradiol ring (Estring), 1033t
Estradiol topical emulsion/gel/solution (Divigel, Elestrin, Estrogel, Estrasorb, Evamist), 1033t
Estradiol transdermal system, 1033t
Estramustine, 470t
p. 2300
p. 2301
Estrasorb (see Estradiol topical emulsion/gel/solution)
Estring (see Estradiol ring)
Estrogel (see Estradiol gel; Estradiol topical emulsion/gel/solution)
Estrogen/progestogen (EPT) therapy, 1031–1032t, 1035t, 1037
adverse effects of, 1035
Estrogens, 503t, 980, 2252–2253
androgen deprivation therapy, 2097
for stress incontinence, 2253
Estrostep, for acne, 829
Eszopiclone (Lunesta), 1767t, 1768–1770
Etanercept, 881, 895, 896t, 904
for PsA, 842–843
Ethacrynic acid, 580
for HF, 277
Ethambutol, 53
dosing of, 1337t
for MAC, 1619
optic neuritis and, 1437–1438
for tuberculosis, 1429t, 1433
Ethanol, 1891
for diabetes, 1146
Ethinyl estradiol
for endometriosis, 1019
OC formulations, 1016
Ethionamide, for tuberculosis, 1430t
Ethosuximide, 1279t
for absence seizures, 1290–1291, 1291t
Ethylenediamine, 822t
Ethynodiol diacetate, 936–937t
Etidronate, for hypercalcemia, 589t, 590
Etodolac, 870t, 888t
Etomidate, 2198
for pediatric intubation, 2200t
Etoposide, 469t, 470t, 1978–1979t, 1981t, 1987, 1990, 1996t, 2003–2005, 2018, 2040t
for aggressive lymphomas, 2042
for blood progenitor cell rescue, 2005
and hepatic dysfunction, 1996t
hypotensive reactions of, 2005
for NSCLC, 2062t
peripheral nerve toxicity of, 1986
for rhabdomyosarcoma, 2010, 2011
for SCLC, 2068–2069, 2068t
Etoricoxib, 1044
Etravirine (ETV), for HIV, 1580t
Etretinate, teratogenic effects, 973t
Eucalyptus, 1721
Evamist (see Estradiol topical emulsion/gel/solution)
Everolimus, 120t, 128, 226, 470t, 722
Evolocumab, 129–131
Exenatide, for type 2 diabetes, 1126–1127, 1135, 1136–1138
Ezetimibe, 130, 1306
adverse effects, 122
clinical pearls, 122
drug interactions, 122
efficacy, 121–122
mechanism of action, 121, 121f
pharmacokinetics/pharmacodynamics, 122
place in therapy, 122
Ezogabine, 1279t, 1281
for seizures, 1285t
F
Factive (see Gemifloxacin)
Famciclovir (FCV), 1648t
adverse effects, 1647t
for genital herpes, 1529–1530, 1530t
for herpes zoster infection, 1652
pharmacokinetics of, 1653t
Famotidine, 977, 1216t, 2163t
H2RA, 483t, 484
for preventing SRMB, 515t
Fampridine, 1224
Fanapt (see Iloperidone)
Fansidar (see Sulfadoxine)
Fat-soluble vitamins, 453
for patients with CF, 457t
FCV (see Famciclovir (FCV))
Febuxostat, 916
drug interactions, 918t
Felbamate, 942t, 1279t, 1281
Felodipine, for chronic stable angina pectoris, 214
Femring (see Estradiol acetate vaginal ring)
Femtrace (see Estradiol acetate tablet)
Fennel, for dysmenorrhea, 1015
Fenofibrate, 124, 124t, 918
Fenofibric acids, 124, 124t
Fenoldopam (Corlopam), 335t
for BP, 341
for hypertensive crisis, 342
for hypertensive emergencies, 342
Fenoprofen, 870t, 888t
Fentanyl, 1178, 1187t
dosage of, 1199t, 1201t
for opioid withdrawalsyndrome, 1880
for pediatric intubation, 2199t
Feraheme (see Ferumoxytol)
Ferric carboxymaltose, for anemia, 1931
Ferric citrate, 620t
Ferric gluconate, for anemia, 1931, 1932, 1933
Ferritin, for anemia, 1930
Ferrous fumarate, for anemia, 1930
Ferrous gluconate, for anemia, 1930
Ferrous sulphate, 1261t
for anemia, 1930
Ferumoxytol, 614, 696
for anemia, 1931, 1932, 1933
Fesoterodine, 2251
Fexofenadine (Allegra), 128, 433t
for rhinitis, 437
Fibric acid, 124t, 914t
adverse effects, 124
clinical pearls, 125
drug interactions, 125
efficacy, 123–124
mechanism of action, 123, 123f
pharmacokinetics/pharmacodynamics, 124
place in therapy, 124–125
Fibrinolytic therapy, 191–192
Fibronectin, 991
Fidaxomicin (Dificid), 1325t
15-methyl prostaglandin F2
α
-tromethamine, 997–998
Finasteride, 2257
for BPH, 2257
for hirsutism, 1012–1013
for prostate cancer, 2099
Fingolimod, 1222, 1228–1229, 1229t
5-α-reductase inhibitors, 2098
5-aminosalicylic acid (5-ASA), 520
for Crohn’s disease, 529
5-flucytosine (5-FC), 1400, 1624
amphotericin B and, 1400
5-fluorouracil, 469t, 1614
5-HT3
antagonists, for CINV, 471, 472t
Flagyl (see Metronidazole)
Flecainide, 1906t
for AF, 315
for HF, 275
and PVC, 323
for WPW, 320
FlexPen, 1086
FlexTouch, 1086, 1087
Flonase Sensimist (see Fluticasone furoate)
Floxin (see Ofloxacin)
Floxuridine, 469t
Fluconazole (Diflucan), 120t, 128, 942t, 1614–1616, 1624, 1624t, 1625, 1626t
a
dv
e
r
s
e
e
ffe
c
t
s
o
f,
1
3
3
4
t
fo
r
C
A
P
D
-
a
s
s
o
c
ia
t
e
d
p
e
r
it
o
nit
is
,
1
4
7
6
t
fo
r
c
hr
o
nic
p
ulmo
n
a
r
y
b
la
s
t
o
my
c
o
s
is
,
1
6
3
7
C
N
S
p
e
n
e
tr
a
t
io
n
o
f,
1
6
4
0
c
r
yp
t
o
c
o
c
c
a
l
dis
e
a
s
e
,
1
6
4
3
do
s
in
g
o
f,
1
3
3
7
t
fo
r
fun
g
a
l
e
n
do
c
a
r
dit
is
,
1
4
0
0
fo
r
fun
g
a
l
in
fe
c
t
io
n
,
1
4
7
9
fo
r
s
e
p
s
is
,
2
1
8
6
t
fo
r
V
V
C
,
1
5
2
5
t
,
1
5
2
6
F
l
u
c
yt
o
s
i
n
e
,
1
6
1
4
–
1
6
1
5
,
1
6
2
5
a
dv
e
r
s
e
e
ffe
c
t
s
o
f,
1
3
3
4
t
,
1
6
4
3
a
n
d
c
r
e
a
t
inin
e
c
le
a
r
a
n
c
e
,
1
6
4
3
c
r
yp
t
o
c
o
c
c
a
l
dis
e
a
s
e
,
1
6
4
3
do
s
in
g
o
f,
1
3
3
7
t
a
n
d
GI
dis
tr
e
s
s
,
1
6
4
3
fo
r
O
I
s
,
1
5
9
8
r
e
n
a
l
e
x
c
r
e
t
io
n
o
f,
1
6
4
3
r
is
k
fa
c
t
o
r
C
,
1
6
3
7
F
l
u
d
a
r
a
b
i
n
e
,
4
6
9
t
,
4
7
0
t
,
1
9
8
5
–
1
9
8
6
,
1
9
9
1
t
,
1
9
9
5
t
fo
r
C
L
L
,
2
0
3
3
e
n
c
e
p
h
a
lop
a
th
ic
t
o
x
ic
ity
o
f,
1
9
8
5
n
e
ur
o
t
o
x
ic
ity
o
f,
1
9
8
5
t
F
l
u
d
r
o
c
o
rt
i
s
o
n
e
,
i
n
t
r
e
a
t
m
e
n
t
o
f
I
D
H
,
6
5
7
F
l
u
m
a
d
i
n
e
(
s
e
e
R
i
m
a
n
t
a
d
i
n
e
)
F
l
u
m
az
e
n
i
l
,
1
7
4
4
,
1
7
4
6
h
e
p
a
t
ic
e
n
c
e
p
h
a
lop
a
thy
,
5
5
3
fo
r
p
e
dia
tr
ic
intub
a
t
io
n
,
2
2
0
0
t
F
l
u
M
i
s
t
,
1
3
6
1
in
flu
e
nz
a
v
a
c
c
in
e
,
1
6
5
7
F
l
u
n
i
s
o
l
i
d
e
,
4
4
1
t
fo
r
a
lle
r
g
ic
r
h
init
is
,
4
4
2
fo
r
B
P
D
,
2
1
7
6
F
l
u
o
r
o
c
yt
o
s
i
n
e
,
1
6
2
4
t
F
l
u
o
r
o
m
e
t
h
o
l
o
n
e
a
c
e
t
a
t
e
,
1
1
6
6
p. 2
3
0
1
p. 2
3
0
2
F
l
u
o
r
o
p
y
ri
m
i
d
i
n
e
,
fo
r
c
o
l
o
n
c
a
n
c
e
r
,
2
0
7
3
F
l
u
o
r
o
q
u
i
n
o
l
o
n
e
s
,
4
6
0
,
4
8
4
,
1
3
7
1
,
1
5
4
9
,
1
7
2
0
a
n
d
a
nt
a
c
id
s
,
4
1
fo
r
b
a
c
t
e
r
ia
l
p
r
o
s
t
a
t
it
is
,
1
5
0
4
fo
r
C
a
mp
y
lo
b
a
c
t
e
r
in
fe
c
t
io
n
,
1
4
5
9
fo
r
C
A
P
,
1
4
1
3
fo
r
C
A
P
D
-
a
s
s
o
c
ia
t
e
d
p
e
r
it
o
nit
is
,
1
4
7
5
fo
r
C
O
P
D
,
4
2
4
fo
r
g
o
n
o
r
r
h
e
a
,
1
5
0
9
fo
r
in
fe
c
t
io
u
s
dia
r
r
h
e
a
,
1
4
4
9
fo
r
M
A
C
,
1
6
1
9
fo
r
n
o
ntyp
h
o
id
a
l
s
a
lmo
n
e
llo
s
is
,
1
4
5
3
–
1
4
5
4
fo
r
s
kin
a
n
d
s
o
ft
t
is
s
u
e
in
fe
c
t
io
n
s
,
1
5
4
9
fo
r
s
ur
g
ic
a
l
p
r
o
c
e
dur
e
s
,
1
3
4
5
t
fo
r
T
B
,
1
4
3
1
for UTI, 1491, 1493
for UTI in pediatric patients, 1497
Fluorouracil, 1972, 1977, 1978, 1978t, 1990
for adverse effects, 2076–2077, 2080
and cerebellar dysfunction, 1985
for colon cancer, 2073
encephalopathic toxicity of, 1985
and hepatic dysfunction, 1996t
neurotoxicity of, 1985t
Fluoxetine (Prozac or Sarafem), 1027t, 1738, 1738t, 1748, 1778
for bipolar depression, 1847
for depression, 2245
for depressive disorders, 1819t, 1820t, 1821t
for diabetes, 2226t
for OCD, 1760
for panic disorder, 1748
for PTSD, 1754
for Raynaud’s disease, 171
and sleep, 1774
for vasomotor symptoms, 1036t
Fluphenazine, 1789t, 1797t, 1799t
decanoate, 1795t
for schizophrenia, 1793t
Flurazepam, 1768
and sleep, 1772
for treatment of insomnia, 1767t
Flurbiprofen, 870t, 888t
Flutamide, for prostate cancer, 2093
Fluticasone
for BPD, 2176
No comments:
Post a Comment
اكتب تعليق حول الموضوع